Comparison of Asymmetric Dimethylarginine Levels Between Stages Three, Four, and Five Non-dialysis of Chronic Kidney Disease
Abstract
Aim: to determine the differences of ADMA level between stages 3, 4, and 5 non-dialysis of chronic kidney
disease (CKD) patients at Outpatient Nephrology Clinic, Dr. Soetomo Hospital. Methods: a cross-sectional
study was conducted on stage 3, 4, and 5 non-dialysis CKD patients at Outpatient Nephrology Clinic, Dr.
Soetomo Hospital, Surabaya from January to February 2015. Stages of CKD were determined based on GFR
estimation according to 4-variable MDRD formula. Statistical analysis of differences in the levels of ADMA in
three subject groups use one-way ANOVA test. Results:seventy-five patients were included in the study. Each
group consisted of 25 patients stage 3, 4, and, 5 non-dialysis patients. Mean age of stage 3, stage 4, and stage
5 non-dialysis CKD patients were respectively 57.12 years, 54.80 years and 53.68 years. The mean levels of
ADMA in stage 3, stage 4, and 5 were 0.62 (0.11) IU/mL, 0.72 (0.16) IU/mL, and 0.73 (0.18) IU/mL respectively.
Analysis of the differences between the groups showed significant differences in ADMA levels (p=0.04), with the
highest difference between stage 3 and stage 5. Conclusion:comparison of ADMA levels showed significant
differences between CKD stages and the level tends to be higher along with increase severity of CKD stages.
disease (CKD) patients at Outpatient Nephrology Clinic, Dr. Soetomo Hospital. Methods: a cross-sectional
study was conducted on stage 3, 4, and 5 non-dialysis CKD patients at Outpatient Nephrology Clinic, Dr.
Soetomo Hospital, Surabaya from January to February 2015. Stages of CKD were determined based on GFR
estimation according to 4-variable MDRD formula. Statistical analysis of differences in the levels of ADMA in
three subject groups use one-way ANOVA test. Results:seventy-five patients were included in the study. Each
group consisted of 25 patients stage 3, 4, and, 5 non-dialysis patients. Mean age of stage 3, stage 4, and stage
5 non-dialysis CKD patients were respectively 57.12 years, 54.80 years and 53.68 years. The mean levels of
ADMA in stage 3, stage 4, and 5 were 0.62 (0.11) IU/mL, 0.72 (0.16) IU/mL, and 0.73 (0.18) IU/mL respectively.
Analysis of the differences between the groups showed significant differences in ADMA levels (p=0.04), with the
highest difference between stage 3 and stage 5. Conclusion:comparison of ADMA levels showed significant
differences between CKD stages and the level tends to be higher along with increase severity of CKD stages.
Keywords
chronic kidney disease; asymmetric dimethylarginine (ADMA); cardiovascular disease
Refbacks
- There are currently no refbacks.